18 results
ARS
2023 FY
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Annual report to shareholders
4:58pm
. European Union New Chemical Entity Exclusivity In the EU, innovative medicinal products approved on the basis of a complete and independent data package … to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if a product is considered to be an innovative
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Regulation FD Disclosure
8:30am
product launch
18 The right field team to launch an innovative rare disease medicine Mission-driven, patient-centric: bringing a novel therapy … indicated for WHIM syndrome Committed to Providing Innovative Solutions Dedicated support and education available through X4Connect and PANTHERx Rare
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
6:30am
development, and to our dedicated employees for making this targeted breakthrough therapy a reality.”
“Effective and innovative treatments … by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise
8-K
EX-99.1
3rfssi5m8bz8c 3b
3 Nov 22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:21am
8-K
EX-99.2
39yiof5tx 7q777mvz
3 Nov 22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:21am
8-K
EX-99.1
bzz5f6783d
5 Aug 22
Regulation FD Disclosure
8:10am
8-K
EX-99.2
hjt7b6i
27 Nov 19
X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class B Warrants
5:18pm
8-K
EX-99.1
akjbhe
27 Nov 19
X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class B Warrants
5:18pm
8-K
EX-99.1
p3f3zdp6zpuqe y0
7 Nov 19
X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights
7:10am
8-K
EX-99.1
0eqmrj5j0gbgaz7
30 Sep 19
Subgroup exceeds target of 50% improvement in median progression-free survival
7:21am
8-K
EX-99.1
ab8cvs0ff
26 Jun 19
Other Events
8:44am
10-K
alqwq
9 Mar 18
Annual report
12:00am
- Prev
- 1
- Next